Assessment of maraviroc exposure-response relationship at 48 weeks in treatment-experienced HIV-1-infected patients in the MOTIVATE studies

CPT: Pharmacometrics and Systems Pharmacology

Volumn 2, Issue 8, 2013, Pages

  Jacqmin, P ^a   Wade, J R ^a   Weatherley, B ^b   Snoeck, E ^a   Marshall, S ^b   McFadyen, L ^b  

^a Exprimo NV   (Belgium)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR; CYTOCHROME P450 3A4 INHIBITOR; CYTOCHROME P450 INHIBITOR; FOSAMPRENAVIR; INDINAVIR; LOPINAVIR; MARAVIROC; PLACEBO; RITONAVIR; SAQUINAVIR; TIPRANAVIR; UNCLASSIFIED DRUG; VIRUS RNA;

ADULT; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CD4 LYMPHOCYTE COUNT; CONCENTRATION RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXPOSURE; DRUG POTENCY; DRUG RESPONSE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; PHASE 3 CLINICAL TRIAL; POST HOC ANALYSIS; PRIORITY JOURNAL; PROBABILITY; PROGNOSIS; RACE; TREATMENT DURATION; TREATMENT OUTCOME; TROPISM; VIRUS LOAD;

EID: 84883417981     PISSN: None     EISSN: 21638306     Source Type: Journal    
DOI: 10.1038/psp.2013.42     Document Type: Article

References (25)

1. Wood, A. & Armour, D. The discovery of the CCR5 receptor antagonist, UK-427,857, a new agent for the treatment of HIV infection and AIDS. Prog. Med. Chem. 43, 239-271 (2005).
2. Gulick, R.M. et al.; MOTIVATE Study Teams. Maraviroc for previously treated patients with R5 HIV-1 infection. N. Engl. J. Med. 359, 1429-1441 (2008).
3. Bellman, R.E. Adaptive Control Processes (Princeton University Press, Princeton, NJ, 1961).
4. Le Moing, V. et al.; APROCO Study Group. Clinical, biologic, and behavioral predictors of early immunologic and virologic response in HIV-infected patients initiating protease inhibitors. J. Acquir. Immune Defic. Syndr. 27, 372-376 (2001).
5. Paredes, R. et al. Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: results from the EuroSIDA study. Arch. Intern. Med. 160, 1123-1132 (2000).
6. Snoeck, E., Wade, J.R., Duff, F., Lamb, M. & Jorga, K. Predicting sustained virological response and anaemia in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) plus ribavirin. Br. J. Clin. Pharmacol. 62, 699-709 (2006).
7. Kakuda, T.N. et al. Pharmacokinetics and pharmacodynamics of the non-nucleoside reverse-transcriptase inhibitor etravirine in treatment-experienced HIV-1-infected patients. Clin. Pharmacol. Ther. 88, 695-703 (2010).
8. Fätkenheuer, G. et al.; MOTIVATE 1 and MOTIVATE 2 Study Teams. Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N. Engl. J. Med. 359, 1442-1455 (2008).
9. Schapiro, J.M. et al. Baseline CD4(+) T-cell counts and weighted background susceptibility scores strongly predict response to maraviroc regimens in treatment-experienced patients. Antivir. Ther. (Lond.) 16, 395-404 (2011).
10. McFadyen, L., Jacqmin, P., Wade, J.R., Weatherley, B. & Chan, P.L.S. Maraviroc (MVC) exposure-efficacy relationship in treatment experienced HIV-1 infected subjects. Poster P4.1/06 presented at the 11th European AIDS Conference, Madrid, Spain (2007).
11. Breiman, L., Friedman, J.H., Olshen, R.A. & Stone, C.J. Classification and Regression Trees (Wandsworth International, Belmont, California, 1984).
12. Gurney, K. An Introduction to Neural Networks (Taylor & Francis, Inc, Bristol, PA, 1997).
13. Harrell, F.E. Jr. Regression Modelling Strategies (Springer, New York, NY, 2001).
14. Fätkenheuer, G. et al. Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat. Med. 11, 1170-1172 (2005).
15. Rosario, M.C., Poland, B., Sullivan, J., Westby, M. & van der Ryst, E. A pharmacokineticpharmacodynamic model to optimize the phase IIa development program of maraviroc. J. Acquir. Immune Defic. Syndr. 42, 183-191 (2006).
16. Weatherley, B. & McFadyen, L. Maraviroc modelling strategy: use of early phase 1 data to support a semi-mechanistic population pharmacokinetic model. Br. J. Clin. Pharmacol. 68, 355-369 (2009).
17. Comté, L., Vrijens, B., Tousset, E., Gérard, P. & Urquhart, J. Estimation of the comparative therapeutic superiority of QD and BID dosing regimens, based on integrated analysis of dosing history data and pharmacokinetics. J. Pharmacokinet. Pharmacodyn. 34, 549-558 (2007).
18. Moyle, G. The Assessing Patients' Preferred Treatments (APPT-1) study. Int. J. STD AIDS 14 (suppl. 1), 34-36 (2003).
19. Blaschke, T.F., Osterberg, L., Vrijens, B. & Urquhart, J. Adherence to medications: insights arising from studies on the unreliable link between prescribed and actual drug dosing histories. Annu. Rev. Pharmacol. Toxicol. 52, 275-301 (2012).
20. Spencer, D.E., Evans, C., Kwakwa, H., Walker, I., Temme, L. & Rawlings, M.K. A meta-analysis of the difference in ART virologic failure rates in randomized clinical trials: Do blacks consistently have lower ART efficacy and poor treatment outcomes? Abstract presented at the XIX International AIDS Conference, Washington, DC, 22-27 July (2012).
21. Weatherley, B., McFadyen, L., Chan, P.L.S. & Marshall, S. Population pharmacokinetic covariate analysis of maraviroc in phase 2b/3 studies in treatment experienced (TE) HIV-1 infected subjects on optimized background therapy (OBT). Poster 17A presented at the 9th International Workshop on Clinical Pharmacology of HIV Therapy, New Orleans, LA, 7-9 April (2008).
22. Wilkin, T.J. et al. Reanalysis of coreceptor tropism in HIV-1-infected adults using a phenotypic assay with enhanced sensitivity. Clin. Infect. Dis. 52, 925-928 (2011).
23. Jacqmin, P., McFadyen, L. & Wade, J.R. Basic PK/PD principles of drug effects in circular/proliferative systems for disease modelling. J. Pharmacokinet. Pharmacodyn. 37, 157-177 (2010).
24. Hastie, T.J. & Tibshirani, R.J. Generalized Additive Models (Chapman & Hall, New York, USA, 1990).
25. Efron, B. & Tibshirani, R.J. An Introduction to the Bootstrap (Chapman & Hall, San Francisco, USA, 1993).